Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06355739
Status:
RECRUITING
Last Update Posted:
2024-04-09
First Post:
2024-02-02
Brief Title:
CD19-targeted CAR T Cell Autotransfusion for the Treatment of RecurrentRefractory B-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma in Children With CD19
Sponsor:
Zhu Xiaofan
Organization:
Institute of Hematology Blood Diseases Hospital China
Study Overview
Official Title:
Phase II Clinical Study on the Safety and Efficacy of Autotransfusion Agents Targeting CD19 Chimeric Antigen Receptor T Lymphocytes BIC-19GG BIC-2019BIC-2219in the Treatment of CD19-positive Children With RelapsedRefractory B-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of BIC-19GG BIC-2019 BIC-2219 in the treatment of relapsedrefractory B acute lymphoblastic leukemialymphoblastic lymphoma in children
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None